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Type II antibodyThe routine use of anti-CD20 monoclonal antibodies (mAbs) has improved patient outcomes in
CD20-positive non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Despite the
clinical success achieved with rituximab, relapses are still common with further improvements in
anti-CD20 mAb efﬁcacy required. Many novel anti-CD20 antibodies are in development, but
obinutuzumab is currently the only type II glycoengineered anti-CD20 mAb in clinical testing.
Obinutuzumab has increased antibody-dependent cell-mediated cytotoxicity, reduced
complement-dependent cytotoxicity and enhanced direct non-apoptotic cell death. In preclinical models,
obinutuzumab induced superior tumor remission compared with rituximab at the equivalent dose
levels, and was active in rituximab-refractory tumors. Obinutuzumab exhibits encouraging efﬁcacy
as monotherapy in NHL, and combined with chemotherapy in relapsed/refractory NHL and
treatment-naïve symptomatic CLL. In a recent randomized, phase III trial in patients with untreated
comorbid CLL, overall response rate was signiﬁcantly greater (78% vs. 65%, P < 0.0001) and median
progression-free survival was signiﬁcantly prolonged (26.7 vs. 15.2 months, P < 0.0001) for obinutuzumab
plus chlorambucil vs. rituximab plus chlorambucil.
Obinutuzumab is a type II anti-CD20 antibody that utilizes distinct mechanisms of action relative to
type I antibodies like rituximab and has led to signiﬁcant clinical improvement over rituximab in a phase
III trial in CLL. Further trials are ongoing to determine whether such improvements in outcome will be
seen in CD20-positive B-cell malignancies.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The anti-CD20 monoclonal antibody (mAb) rituximab
(Rituxan, MabThera) has improved clinical outcomes for
patients with a broad range of B-cell malignancies. Phase II trials
demonstrated single-agent activity and durable clinical responses
with rituximab, leading to health authority approval in the US in
1997, and in the EU in 1998. However, it was not until randomized
phase III trials of combined rituximab with chemotherapy showed
an improvement in overall survival (OS), that this became thestandard of care in B-cell non-Hodgkin’s lymphoma (NHL) and
chronic lymphocytic leukemia (CLL) [1–7]. However, with up to
40% of diffuse large B-cell lymphoma (DLBCL) patients still dying
of lymphoma, and most patients with follicular lymphoma (FL)
or CLL relapsing and eventually developing chemotherapy- and
rituximab-refractory disease, there remains room for improvement
[8,9]. Given rituximab’s success, the development of anti-CD20
mAbs with enhanced or novel effector mechanisms may yield
improved efﬁcacy and/or show activity in rituximab-refractory
patients. This article discusses the preclinical and emerging clinical
trial data using obinutuzumab (GA101; GAZYVA, GAZYVARO).How do structural components deﬁne type I and type II anti-
CD20 mAb activity?
Anti-CD20 mAbs are classiﬁed by their CD20-binding character-
istics, ability to induce complement-dependent cytotoxicity (CDC),
Table 1
Summary of functional differences between type I and type II mAbs.
Type I mAbs (rituximab,
ofatumumab, veltuzumab,
ublituximab)
Type II mAbs (obinutuzumab,
tositumomab)
Localization of CD20 into lipid
rafts, increasing CDC
No localization of CD20 into lipid rafts,
which leads to reduced CDC
No homotypic adhesion, low cell
death/apoptosis
Homotypic adhesion, resulting in
noncaspase-dependent direct cell death
Full CD20 binding capacity at
saturating conditions
Half-maximal CD20 binding at saturating
conditions, stimulating greater levels of
apoptotic induction than type I mAbs
CD20 modulation Less or no CD20 modulation
Induce ADCC
Induce ADCP
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, anti-
body-dependent cellular phagocytosis; CDC, complement-dependent cytotoxicity;
mAbs, monoclonal antibody.
Table 2
Functional comparison of Fc- or glycoengineered anti-CD20 mAbs to rituximab.
Name (INN) Company ADCC CDC Cell death
Rituximab Roche + + +
Obinutuzumab [23] Roche +++ +/ +++
Ocaratuzumab [15] Lilly +++ + +
PRO131921 [111] Genentech +++ + +
Ublituximab [17,43] LFB/TG Therapeutics +++ + +
KM3065 [112,113] Kyowa Hakko Kirin +++ + +
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, com-
plement-dependent cytotoxicity; mAbs, monoclonal antibodies; +, activity induced
by rituximab; ++ and +++, increased activity compared with rituximab; , reduced
activity compared with rituximab.
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mAbs investigated are of type I (rituximab, ofatumumab, ublitux-
imab, veltuzumab, ocaratuzumab; Table 2) [15–19], and binding
to CD20 on lymphoma cells induces rapid translocation of
anti-CD20 mAb–CD20 antigen complexes into lipid rafts (Fig. 1A)
[13]. This complex formation leads to strong CDC, but only weak
direct apoptosis (cell death) [10–12,20,21]. Type I and type II mAbs
both induce antibody-dependent cell-mediated cytotoxicity
(ADCC) and antibody-dependent cellular phagocytosis (ADCP)
through immune effector cell interactions [22]. Conversely, type
II mAbs (tositumomab, obinutuzumab) potently induce direct cell
death but do not localize mAb–CD20 antigen complexes into lipidFig. 1. The effects of type I and type II anti-CD20 mAb binding to CD20 on FccRIIb inter
CD20 but also to FccRIIb. Simultaneous engagement of FccRIIb could trigger intern
obinutuzumab, do not generally engage CD20 in a manner that would permit simultane
comparatively reduced. Adapted from MAbs 5:22-33, 2013; 2013 Landes Bioscience [1rafts (Fig. 1B), resulting in low levels of CDC [12,13,23]. CDC
induction by obinutuzumab is >10- to 100-fold less than with
the type I mAbs rituximab and ofatumumab [24], resulting in a
further-increased capacity to bind and activate natural killer (NK)
cells in the presence of complement [25]. FccRIIb-mediated CD20
internalization has been implicated in reduced rituximab
efﬁcacy. Conversely, type II CD20 antibodies result in reduced
FccRIIb-induced CD20 internalization, which may further enhance
immune effector function [26].
Antibody activity may be manipulated ﬁrstly by changing the
target CD20 epitope bound by the mAb or secondly by altering
the Fc region to enhance immune effector cell activity (ADCC,
ADCP). For example, compared with rituximab, ofatumumab
exhibits increased CDC by binding to a different CD20 epitope
[24]. Fc alterations are illustrated by ocaratuzumab (AME-133v),
which exhibits increased ADCC via an amino acid substitution in
the Fc domain that alters Fcc receptor (FccR) interaction [27].
Enhancing the direct effects mediated by type II CD20 antibodies
Compared with rituximab, obinutuzumab ﬁrstly targets a
different, but overlapping, epitope of the CD20 extracellular
domain [14]. The selection of a particular valine-for-leucine
substitution in the elbow hinge region of obinutuzumab appears
to have considerable impact on its in vitro activity (Fig. 2). These
two modiﬁcations result in increased in vitro direct cell death
induction, demonstrated in various tumor cell lines (FL, mantle cell
lymphoma [MCL], DLBCL, CLL) [23,28,29], most likely by affecting
the ﬂexibility and angle of antibody binding to CD20.
Obinutuzumab appears to cause cell death via homotypic
aggregation (the clustering of lymphoma cells by bound antibody),
which proceeds through a caspase-independent, nonapoptotic,
lysosome-mediated mechanism involving reactive oxygen species
[23,28–33]. This mechanism is independent of effector cell
engagement and has also been reported for other antigens such
as e.g. HLA-DR [34] or CD37 [35], which may be relevant in
patients with impaired immunity.
Enhancing Fc effector function
The oligosaccharide composition of the antibody Fc portion
affects its afﬁnity for FccRIII on the immune effector cell
surface (NK cells, neutrophils, macrophages/monocytes) [36].
Glycoengineering the carbohydrate moiety of obinutuzumabnalization. (A) There is potential for type I mAbs, like rituximab, to bind not only to
alization of antibody via lipid rafts. (B) In contrast, type II antibodies, such as
ous FccRIIb binding. Consequently, internalization of type II mAbs via lipid rafts is
3]. mAb, monoclonal antibody.
Fig. 2. Structure of obinutuzumab and the Fc-attached glycan tree modiﬁed by glycoengineering. The illustration shows the main peptide chains of obinutuzumab that
compose the Fab antigen-binding domain (VH, VL, CH1, and CH) and the Fc domain (CH2 and CH3) which interacts with FccRs. The glycan tree is attached to asparagine 297. The
core fucose that is not added to the glycan tree is highlighted with a dashed box. ADCC, antibody-dependent cell-mediated cytotoxicity, CH, constant heavy chain; CL, constant
light chain; Fuc, fucose; Gal, galactose; GlcNAc, N-acetylglucosamine; Man, mannose; NeuAc, N-acetylneuraminic acid; VH, variable heavy chain; VL, variable light chain.
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ies like rituximab (Fig. 2). Defucosylated moieties have increased
afﬁnity for FccRIIIa and FccRIIIb, and interact more effectively with
FccRIII-expressing effector cells [37–40], increasing recruitment
capacity and activation to ultimately improve in vitro ADCC and
ADCP compared with fully fucosylated antibodies [23,41,42].
Consequently, antibodies like obinutuzumab or ublituximab
induce NK cell-mediated ADCC to a greater extent than rituximab
or ofatumumab, with similar levels of ADCP [17,24,43]. However,
in the presence of physiologic levels of immunoglobulins,
monocyte/macrophage-mediated phagocytosis (ADCP) and ADCC
are enhanced [42]. Furthermore, obinutuzumab activates
neutrophils and mediates phagocytosis through FccRIIIb more
efﬁciently than rituximab [41]. Glycoengineering also appears to
overwrite inhibition by inhibitory KIR receptors [44].
Preclinical observations with obinutuzumab
In normal and malignant B-cell lines and xenograft models,
obinutuzumab induced superior activity to rituximab, even under
rituximab-saturating dose/equivalent exposure conditions [23].
In a DLBCL xenograft model progressing under rituximab treat-
ment, tumors did not respond to further rituximab, but progression
was delayed and tumor volume reduced with obinutuzumab.
Obinutuzumab-chemotherapy combinations also prolonged sur-
vival to a greater extent than rituximab combinations in a mouse
MCL model [23,45].
In a cynomolgus monkey model, rituximab and obinutuzumab
both induced complete peripheral blood B-cell depletion, whereas
obinutuzumab induced signiﬁcantly greater lymphoid and splenic
B-cell depletion [23]. Similarly, obinutuzumab induced greater
levels of B-cell depletion than rituximab in whole blood from
healthy volunteers [23,24], and blood from patients with CLL
[46,47].
What are the potential clinical implications of the different
mechanisms of action of obinutuzumab?
Resistance mechanisms to type I anti-CD20 mAbs are incom-
pletely understood. Contributing factors include intrinsic tumor
cell alterations (e.g., loss of CD20 from the lymphoma cell surface,as observed in rare rituximab-refractory patients) [29], and host
immunologic environment [48]. Tumor cell resistance to apoptosis
may predict impaired response/resistance to chemotherapy and
immunochemotherapy. Fc–FccR interaction between immune
effector cells and CD20-bound antibody is essential to induce
antibody-dependent cell killing mechanisms including ADCC and
ADCP [49]. Both activating and inhibitory FccRs modulate the
cytotoxicity of rituximab against tumors in mice [50]. In normal
mouse B cells [51,52], and adoptively transferred primary murine
lymphoma [53] from syngeneic mouse models, FccRs are required
for anti-CD20-mediated B-cell depletion. FccR polymorphisms also
appear to be clinically important; a polymorphism at residue 158
that substitutes valine for phenylalanine increases afﬁnity for
mAbs, and is associated with higher response rates in FL patients
receiving rituximabmonotherapy [54]. The signiﬁcance is less clear
for immunochemotherapy, with polymorphisms predictive of
outcome in some studies of DLBCL and FL [55–58] but not in others
[59–63]. FccR polymorphisms may only be clinically relevant for
rituximab monotherapy, or in patients with limited rituximab
exposure [64]. The impact of FccR polymorphisms has not been
observed in CLL, for rituximabmonotherapy or immunochemother-
apy, possibly due to overall impaired effector cell function in
CLL [65,66]. These results suggest that disease-speciﬁc primary
mechanisms of action may underlie mAb-mediated cell death.
Emerging data suggest a ‘‘vaccination’’ effect with anti-CD20
antibodies, whereby cell death enhances dendritic cell maturation
and T-cell activation to produce an antilymphoma immune
response [67]. ‘‘Proof-of-principle’’ data have demonstrated an
increased level of FL idiotype-speciﬁc T cells relative to baseline
after rituximab treatment in ﬁve FL patients [68]. This long-term
‘‘vaccination’’ effect, which may prolong survival, has been
demonstrated in mice expressing human CD20 [69]. It appears to
be predominantly mediated by Fc–FccR interactions including
FccRIIIa, with the Fc component required for long-lasting tumor
protection in immunocompetent mice [69].
The apparent importance of Fc–FccR interactions for effector
cell-mediated killing of lymphoma cells, as well as other potential
effects following mAb treatment, has been a key consideration in
the development of next-generation mAbs. Greater understanding
of these mechanisms and Fc–FccR interactions in different clinical
contexts may facilitate the optimal use of anti-CD20 mAbs. For
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immunomodulatory agent that may stimulate T- and NK-cell
cytotoxicity [70], may provide substantially high response rates
in previously untreated indolent NHL patients [71]. Given the
improved in vitro ADCC and ADCP of obinutuzumab compared
with rituximab, further investigations into such combinations are
worthwhile. A phase I/II clinical trial (NCT01582776) evaluating
combination treatment with obinutuzumab plus lenalidomide is
underway.
Obinutuzumab dosing
Preclinical data show that obinutuzumab has superior efﬁcacy
over rituximab at the same dose of mAb, indicating that enhanced
clinical efﬁcacy may not be simply related to the higher mAb dos-
ing of obinutuzumab (1000 mg) compared with standard ritux-
imab dosing (375 mg/m2 in NHL and 375 then 500 mg/m2 in
CLL). No increase in response was observed with an increased dose
of rituximab monotherapy (from 375 to 500 mg/m2) in a phase II
study in aggressive NHL [72], and although the rituximab
500 mg/m2 dose in CLL was based on a dose–response relationship
[73], the addition of two extra doses of rituximab to each cycle of
standard rituximab with ﬂudarabine and cyclophosphamide (FC)
in previously untreated CLL did not increase efﬁcacy [74]. The dose
for obinutuzumab was based on dose-escalation studies and
optimized via pharmacokinetic modeling [75,76].
Clinical experience with obinutuzumab
The improved in vitro and preclinical activity vs. type I mAbs,
led to obinutuzumab becoming the ﬁrst glycoengineered type II
anti-CD20 mAb in clinical development.
Early-phase clinical trials in NHL
Obinutuzumab elicited responses in rituximab-refractory dis-
ease in three phase I trials [77–79]. In one study, 21 patients with
relapsed/refractory NHL were administered eight 21-day cycles of
obinutuzumab monotherapy at doses ranging from 50/100 to
1200/2000 mg. There were nine responders (ﬁve complete
responses [CR], four partial responses [PR]s) [77]. In another study,
22 patients, including ﬁve with CLL, received four infusions of
obinutuzumab 200 to 2000 mg weekly for 4 weeks, with mainte-
nance in responding patients. Five patients achieved PR and 12
stable disease at the end of induction; eight patients received
maintenance therapy, during which three patients experienced
an improved response [78]. In both trials, investigators reported
that obinutuzumab did not induce signiﬁcant activation of the
complement cascade [77,78]. In a Japanese dose-ﬁnding study,
seven of 12 patients with relapsed/refractory NHL experienced
responses to obinutuzumab monotherapy (2 CR and 5 PR) [79].
Adverse events (AEs) were similar in nature to those observed
for other anti-CD20 antibodies. Infusion-related reactions (IRRs)
were common at ﬁrst infusion, with few grade 3 or 4 events, and
no other speciﬁc patterns that could be attributed to obinu-
tuzumab [77,78]. A few patients with MCL experienced rapid
depletion of circulating B cells, resulting in clinically signiﬁcant
tumor lysis syndrome. Overall, ﬁve patients experienced grade 3
or 4 neutropenia, which resolved with or without growth factor
administration [78].
Phase II trials of obinutuzumab in NHL
Phase II studies of obinutuzumab monotherapy in patients with
relapsed/refractory indolent NHL (n = 40) or aggressive NHL(n = 40) have been conducted [80,81]. Based on pharmacokinetic
observations in phase I [80], two dose regimens of obinutuzumab
were evaluated: 1600/800 mg (1600 mg of obinutuzumab infused
on days 1 and 8 of cycle 1 and 800 mg infused on day 1 of cycles
2–8) and 400/400 mg (400 mg given on days 1 and 8 of cycle 1,
and then every 3 weeks for seven further cycles) [81]. The
1600/800-mg regimen achieved a response rate of 55% in indolent
NHL and 32% in aggressive NHL, whereas the response rates for the
400/400-mg regimen were 17% in indolent NHL and 24% in aggres-
sive NHL. The response rate in rituximab-refractory patients
receiving the 1600/800-mg dose was 50% (5/10) for indolent NHL
[81] and 33% (4/12) for aggressive NHL [80]. Of the 40 patients
with heavily pretreated aggressive NHL (median of three prior
treatments), 63% of whom were rituximab-refractory, obinu-
tuzumab yielded a best overall response rate (ORR) of 32% in
patients with DLBCL (8/25) and 27% in those with MCL(4/15)
[80,81]. ORRs for obinutuzumab were comparable with those for
rituximab (30%) in a less heavily pretreated, rituximab-naïve pop-
ulation [82]. These results also compare favorably with those
reported for other type I antibodies; for example, ofatumumab
achieved an ORR of 11% in a similar patient population with
relapsed/refractory DLBCL previously exposed to rituximab [83].
In the randomized phase II GAUSS trial, 175 patients with
heavily pretreated, relapsed indolent NHL received four weekly
infusions of obinutuzumab 1000 mg or rituximab 375 mg/m2.
All patients had previously responded to rituximab. The
end-of-induction investigator-assessed response rates for obinu-
tuzumab and rituximab in patients with FL were 43.2% and
38.7%, respectively, and the CR rates were 10.8% and 6.7%, respec-
tively. A central independent review of responses reported ORRs of
43.2% and 28.0% for obinutuzumab and rituximab, respectively;
however, no differences in PFS were observed, albeit that the study
was not powered to determine such differences. The toxicities of
both treatments were similar, but more patients presented with
cough in the obinutuzumab arm (10% vs. 1%) and a greater propor-
tion experienced IRRs (any grade, 72% vs. 49%; grade 3 or 4, 11% vs.
5%) [84].
Use of obinutuzumab in combination with chemotherapy has
also been explored. In the phase Ib GAUDI study, patients with
relapsed/refractory FL were assigned to either CHOP (six to eight
cycles every 3 weeks) or FC (four to six cycles, every 4 weeks)
per standard institutional practice and then randomly assigned
to either obinutuzumab 1600/800 mg or 400/400 mg. At the end
of induction, 96% of patients receiving obinutuzumab plus CHOP
and 93% of those receiving obinutuzumab plus FC responded. Of
the 14 rituximab-refractory patients, all experienced at least a
PR. The most common treatment-related AE was IRR; most were
grade 1 or 2 [85].Early-phase clinical trials in CLL
In a phase I trial, 13 patients with heavily pretreated
relapsed/refractory CLL received eight 21-day cycles of obinu-
tuzumab (400–200 mg). Reduced B-cell counts were apparent from
ﬁrst dose and maintained throughout treatment. Eight patients
(62%) achieved PR. However, the end-of-treatment response in
phase II was lower; 25% (4/16) achieved PR [86], a difference
attributed to differences in tumor burden between phases;
serum concentrations of type I mAbs are lower in patients with
higher tumor burden, which is associated with poorer prognosis
[87–90]. Overall, of the 12 patients who responded to
obinutuzumab, nine had a limited baseline tumor burden
(sum of product of diameter below 2000 mm2) [86].
In the phase II GAGE study evaluating 1000 vs. 2000 mg
obinutuzumab, activity was seen at both doses (ORR 49% and
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Grade 3–4 IRRs were conﬁned to cycle 1 [91].
In the phase Ib GALTON trial, measuring preliminary efﬁcacy
and safety of obinutuzumab in combination with bendamustine
or FC, ORR was 90% and 62% respectively. IRRs were again the most
common AE (88% patients; grade 3–4 20%) [92].
Phase III trials in CLL
Elderly patients with CLL and those with comorbidities are rou-
tinely treated with chlorambucil monotherapy, as no conclusive
evidence exists for the superiority of other currently available
options [93]. The phase III CLL11 trial investigated patients with
previously untreated comorbid (Cumulative Illness Rating Scale
score >6) CLL and compared the safety and efﬁcacy of six 28-day
cycles of combination treatment with either obinutuzumab
(1000 mg on days 1, 8, and 15 of cycle 1 then day 1 of cycles 2
to 6 [a protocol amendment allowed the administration of the ﬁrst
dose of obinutuzumab over 2 days]) or rituximab (375 mg/m2 on
day 1 of cycle 1 then 500 mg/m2 on day 1 of cycles 2–6) plus
chlorambucil (0.5 mg/kg on days 1 and 15 of each cycle), with
chlorambucil monotherapy [94].
Stage 1 investigated the beneﬁt of adding obinutuzumab or
rituximab to chlorambucil; 118 patients were randomly assigned
to chlorambucil alone, 238 to obinutuzumab plus chlorambucil,
and 233 to rituximab plus chlorambucil. In stage 1, 77.3% of
patients receiving obinutuzumab plus chlorambucil responded to
treatment (22.3% CR) vs. 31.4% of patients receiving chlorambucil
only (0% CR). A higher end-of-treatment ORR was also observed
for rituximab plus chlorambucil (65.7%; 7.3% CR) vs. chlorambucil
only (31.4%; 0% CR). Interestingly, minimal residual disease
(MRD)-negativity (by polymerase chain reaction) was not observed
in the chlorambucil-only arm, but was achieved with obinu-
tuzumab plus chlorambucil (31.1% peripheral blood and 17.0%
bone marrow) and in a small percentage of those treated with
rituximab plus chlorambucil (2.0%, peripheral blood; 2.8%, bone
marrow) [94]. At a median observation time of 23 months,
investigator-assessed median PFS was signiﬁcantly greater with
obinutuzumab plus chlorambucil vs. chlorambucil alone (26.7 vs.
11.1 months; hazard ratio [HR], 0.18; P < 0.0001) [94]. Similarly,
compared with chlorambucil alone, rituximab plus chlorambucil
was associated with signiﬁcantly prolonged investigator-assessed
median PFS (16.3 vs. 11.1 months; HR, 0.44; P < 0.0001) [94].
Stage 2 randomized additional patients to compare obinu-
tuzumab with rituximab when combined with chlorambucil; 333
patients received obinutuzumab plus chlorambucil, and 330
received rituximab plus chlorambucil. The end-of-treatment ORR
was signiﬁcantly greater with obinutuzumab plus chlorambucil
vs. rituximab plus chlorambucil (78.4% vs. 65.1%, P < 0.0001), with
a threefold increased proportion of patients with CR (20.7% vs.
7.0%). The percentages of patients negative for MRD in the bone
marrow (19.5% vs. 2.6%, P < 0.0001) and blood (37.7% vs. 3.3%,
P < 0.0001) were also signiﬁcantly greater for obinutuzumab plus
chlorambucil. After a median observation time of 18.7 months,
median PFS was signiﬁcantly prolonged with obinutuzumab plus
chlorambucil relative to rituximab plus chlorambucil (26.7 vs.
15.2 months; HR, 0.39; P < 0.0001). OS was signiﬁcantly improved
in the obinutuzumab plus chlorambucil arm compared with
chlorambucil monotherapy (HR for death, 0.41; P = 0.002), with
no signiﬁcant difference shown for the rituximab plus chlorambucil
arm vs. chlorambucil monotherapy (HR, 0.66; P = 0.11). However,
there was no signiﬁcant difference in OS between the combination
therapy arms (HR, 0.66; P = 0.08) [94]. In a later update to this
study, the PFS advantage for obinutuzumab plus chlorambucil
compared with rituximab plus chlorambucil (median PFS 29.2 vs.
15.4 months; HR, 0.40; P < 0.001) was conﬁrmed, although OS datawere immature at the time of reporting, there were only 45/333
deaths in the obinutuzumab plus chlorambucil arm and 63/330
in the rituximab plus chlorambucil arm [95].
The COMPLEMENT 1 study, which compared ofatumumab plus
chlorambucil with chlorambucil alone in untreated CLL reported a
statistically signiﬁcant improvement in median PFS (22.4 vs.
13.1 months; P < 0.001) in 221 patients randomized to ofatu-
mumab (300 mg day 1 and 1000 mg day 8, then 1000 mg day 1
of each 28-day cycle) plus chlorambucil (10 mg/m2 on days 1–7
of each cycle) compared with 226 patients randomized to chloram-
bucil alone [96].Safety proﬁle of obinutuzumab
In stage 1 of the phase III CLL11 study, gradeP3 IRRs occurred
in 21% of patients who received obinutuzumab, all at ﬁrst infusion
[97]. In stage 2, the incidence of grade P3 IRRs was higher with
obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil
(20% vs. 4%) [94]. Interestingly, this difference was greater than
that observed for gradeP3 IRRs between obinutuzumab and ritux-
imab when given as monotherapy for relapsed indolent NHL
(11% vs. 5%, respectively) [78]. The higher afﬁnity of obinutuzumab
for FccRIII binding to CD20 on peripheral cells may lead to stronger
FccR activation and subsequent target mediated cytokine release,
particularly in ﬁrst-line treatment of patients with high peripheral
CLL counts. Indeed, CLL patients with higher CD20 expression,
FccRIII expression, or expressing the higher afﬁnity FccRIII
genotype are at increased risk of developing IRRs [98]. A signiﬁcant
decrease in circulating B cells and increase in the
pro-inﬂammatory cytokines IL-6, IL-8, TNF-a, and IFN-c has also
been shown following the ﬁrst infusion of obinutuzumab [99],
which may account for the increased incidence of IRRs. Preliminary
safety data from GREEN showed fewer grade P3 IRRs with a split
initial dose of obinutuzumab over 2 days in Cycle 1 (25 mg on
Day 1 and 975 mg on Day 2), and lower infusion rate (the Day 1
dose was given at 12.5 mg/h); however, discontinuation
levels were similar to previously reported studies [100]. IRRs were
well managed with acetaminophen/paracetamol, antihistamine
(30 min prior to ﬁrst dose and for subsequent doses if required)
and steroid (prednisone 100 mg iv at least one hour before the
Cycle 1 obinutuzumab dose on Day 1 and Day 2) premedication.
Although stage 1 data from the phase III CLL11 study showed an
increased incidence of grade P3 neutropenia among patients
receiving obinutuzumab plus chlorambucil vs. chlorambucil alone
(35% vs. 16%), the rate of grade P3 infection was slightly higher
with chlorambucil monotherapy (14% vs. 11%) [94]. Similar trends
were observed in stage 2, with slightly higher rates of grade P3
neutropenia and thrombocytopenia for obinutuzumab plus chlo-
rambucil vs. rituximab plus chlorambucil (33% vs. 28% and 11%
vs. 28%, respectively) and similar rates of grade P3 infection
(12% vs. 14%) [94]. The observed incidence of neutropenia may
be related to enhanced neutrophil consumption due to ADCP
[41]. The potential longer-term signiﬁcance of this increased neu-
tropenia remains to be determined and further careful observation
is required.Will obinutuzumab be effective in rituximab-refractory
disease?
Rituximab resistance is now an important challenge in the
treatment of B-cell malignancies. There are numerous, physiologi-
cally diverse mechanisms by which rituximab resistance can
develop, including tumor-speciﬁc mechanisms (reduced tumor
penetration, impaired mAb binding, loss/downregulation of CD20,
resistance of tumor cells to mAb-effector mechanisms) and factors
T. Illidge et al. / Cancer Treatment Reviews 41 (2015) 784–792 789related to patient physiology (increased mAb metabolism,
impaired immune effector cell recruitment or function) [101].
Loss of the CD20 antigen from lymphoma cells was ﬁrst
reported by Davis et al. [102], and it was subsequently shown that
B cells with signiﬁcantly reduced CD20 levels could emerge follow-
ing rituximab infusion in CLL patients [103]. CD20 loss contributes
signiﬁcantly to the lack of response to rituximab in some patients
[104], and occurs by at least two mechanisms. The ﬁrst involves
the ‘‘shaving’’ of rituximab/CD20 complexes from the cell surface,
mediated by phagocytic cells when immune effector mechanisms
become saturated by high levels of circulating target antigen
[105,106]. A second mechanism involves internalization of CD20
into lysosomes via endocytosis; and occurs with type I, but not
type II, anti-CD20 mAbs [107]. Modulation of CD20 location may
underlie the reduced clinical efﬁcacy of type I mAbs in CLL and
MCL [26,107]. Obinutuzumab monotherapy has displayed
signiﬁcant activity in rituximab-refractory disease in phase II stud-
ies [80,81,108], which justiﬁed a randomized phase III study
(GADOLIN, NCT01059630) investigating whether obinutuzumab
plus bendamustine confers clinically meaningful beneﬁt vs.
bendamustine monotherapy in rituximab-refractory indolent
NHL; this study was reported early as the primary endpoint had
been met at a pre-planned interim analysis.Conclusions
Obinutuzumab is a glycoengineered, type II anti-CD20 mAb
with different mechanisms of action to rituximab, including
increased induction of direct cell death and enhanced ADCC/ADCP.
Preclinical data show that obinutuzumab has superior efﬁcacy over
rituximab at the same dose of mAb.
In CLL11, no relevant induction of MRD negativity was achieved
with the addition of rituximab to chlorambucil for CLL, as was
apparent with the addition of rituximab to FC in the CLL8 study
[109]. Thus, the markedly increased MRD negativity with G-Clb
vs. R-Clb in CLL11 argues against a sole dose effect, but infers a dif-
ferent biological mechanism of disease eradication in CLL. Owing
to differences in the chlorambucil schedules used, in the absence
of a direct comparison of the type I anti-CD20 mAb ofatumumab
with the type II mAb obinutuzumab, it is not possible to determine
which is the superior mAb. Preclinical insights regarding CD20
expression and modulation imply that the mechanism of action
of type II anti-CD20 mAbs is more advantageous than that of type
I mAbs in B-cell malignancies. To date, clinical data suggest that
differences in activity may be more pronounced in B-cell malig-
nancies such as CLL and MCL, albeit numbers of MCL are low. It
is possible that differences may be seen across different B-cell
malignancies and no signal of superiority has yet been seen in
FL; where there was no signiﬁcant PFS increase for obinutuzumab
vs. rituximab in the GAUSS study [84].
Obinutuzumab underpins a number of ongoing phase III
clinical trials in patients with untreated, and rituximab-
refractory, indolent NHL. In particular, direct comparisons of
obinutuzumab-CHOP vs. R-CHOP in untreated patients with
CD20-positive DLBCL, and obinutuzumab or rituximab plus
CHOP, CVP (cyclophosphamide, vincristine, and prednisone), or
bendamustine in untreated advanced indolent NHL will provide
further evidence of the potential for improved outcomes with
obinutuzumab in other B-cell malignancies.
In CLL, therapeutic alternatives and scheduling options are com-
plex, with high clinical activity noted for many novel agents. Many
trial groups are considering ‘‘mild’’ short-acting chemotherapy to
debulk the tumor, before administering at least two or three of
the best novel agents: for example, ABT-199 plus obinutuzumab,
ibrutinib plus obinutuzumab, or idelalisib/ibrutinib/ABT-199[110]. These combinations will need rigorous testing in well-
designed clinical trials assessing MRD status.
Further phase III clinical trial data are eagerly awaited including
obinutuzumab or rituximab plus chemotherapy in patients with
previously untreated indolent NHL (NCT01332968); bendamustine
with or without obinutuzumab in rituximab-refractory indolent
NHL (NCT01059630); obinutuzumab or rituximab plus chemother-
apy in ﬁrst-line DLBCL (NCT01659099, NCT01287741).
Ongoing trials will provide evidence of whether patient
outcomes in other B-cell malignancies can be further improved
by the introduction of this novel mAb.Conﬂicts of interest
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